Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer-Reference-Cited by-同舟云学术

Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer

Published:2018-12 Issue:12 Volume:29 Page:2348-2355
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Kruger S.,Heinemann V.,Ross C.,Diehl F.,Nagel D.,Ormanns S.,Liebmann S.,Prinz-Bravin I.,Westphalen C.B.,Haas M.,Jung A.,Kirchner T.,von Bergwelt-Baildon M.,Boeck S.,Holdenrieder S.

Funder

Sysmex Inostics

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/29/12/2348/27342110/mdy417.pdf

Reference19 articles.

1. Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030;Quante;Cancer Med,2016

2. Translational research in pancreatic ductal adenocarcinoma: current evidence and future concepts;Kruger;World J Gastroenterol,2014

3. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology;Tempero;J Natl Compr Canc Netw,2017